Skip to main content
An official website of the United States government
Principal Investigator
Lucile Lauren Adams-Campbell
Awardee Organization

Georgetown University
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

National Capital Area (NCA) NCI Community Oncology Research Program (NCORP)

The NCA NCORP (funding support from 5UG1CA239758-06) is based at Georgetown Lombardi Comprehensive Cancer Center (LCCC), and consists of Medstar Georgetown University Hospital (MGUH) and MedStar Washington Hospital Center (MWHC) as the primary affiliate, with a catchment area comprising 58.9% understudied populations within Washington, D.C. and adjacent counties in Maryland and Virginia. Cancer burden is greatest among representative populations in our catchment area as evident by some of the highest mortality rates in the nation for breast, prostate, and colorectal cancers. The NCA NCORP proposes to address one of the most significant factors associated with this variance in cancer burden - limited access to optimal and cutting-edge prevention, cancer control, and cancer care delivery by increasing awareness and providing access to cancer clinical trials. LCCC’s Office of Health Disparities Research, represents the community outreach arm that is led by Dr. Adams-Campbell, that has established viable academic-community partnerships that enable the NCA NCORP to conduct clinical research in areas of prevention, control, screening, health variance, and cancer care delivery among the representative populations of interest. In light of an aging population and the increasing number of cancer survivors, this NCORP has the expertise and leadership as evident by demonstrable research in these areas that address cancer control and patient centered cancer care delivery. Furthermore, the ability to address cancer prevention and control among adolescents and young adults (AYA) is also a key strength of our team. The NCA NCORP will address the needs of our catchment area via cancer prevention, control, screening as well as treatment and imaging studies.

Publications

  • Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Jan 10;41(2):186-197. Epub 2022 Sep 27. PMID: 36166727
  • Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine. 2023 Mar 2;388(9):813-823. PMID: 36856617